| 1. |
- Bidartondo, Martin, et al.
(författare)
-
Preserving accuracy in GenBank
- 2008
-
Ingår i: Science. ; 319:5870
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
- Schmitz, Alexander, et al.
(författare)
-
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission : results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
- 2022
-
Ingår i: BMC Cancer. - : BMC. - 1471-2407 .- 1471-2407. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with >= 3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4-2.3 months). Minimal malignant plasma cells detection limit was 4 x 10-5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression.
|
|
| 3. |
- Andersen, Henrik Rasmus, et al.
(författare)
-
Estrogenic personal care products in a greywater reuse system
- 2007
-
Ingår i: Water Science and Technology. - : IWA Publishing. - 0273-1223 .- 1996-9732. ; 56:12, s. 45-49
-
Tidskriftsartikel (refereegranskat)abstract
- The occurrence and fate of parabens in a greywater system was assessed. The potential for removal of residual paraben concentrations in effluent greywater with chlorine dioxide was also investigated. The influent to the greywater plant was characterised by considerable variation, with concentrations from below the detection limit to 40 μg/L and the five commonly used parabens in consumer products were frequently detected. After the biological treatment only two paraben were detected with concentration from 65–120 ng/L. Chlorine dioxide treatment of the biologically treated effluent with dosages down to 0.75 mg/L resulted in more than 97% reduction of all parabens. Formation of the by-product chloroform was insignificant from the chlorine dioxide treatment.
|
|
| 4. |
- Antoniou, Maria G., et al.
(författare)
-
Required ozone doses for removing pharmaceuticals from wastewater effluents
- 2013
-
Ingår i: Science of the Total Environment. - Amsterdam : Elsevier BV. - 1879-1026 .- 0048-9697. ; 456, s. 42-49
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the this study was to investigate the ozone dosage required to remove active pharmaceutical ingredients (APIs) from biologically treated wastewater of varying quality, originated from different raw wastewater and wastewater treatment processes. Secondary effluents from six Swedish wastewater treatment plants (WWTP) were spiked with 42 APIs (nominal concentration 1 mu g/L) and treated with different O-3 doses (0.5-12.0 mg/L ozone) in bench-scale experiments. In order to compare the sensitivity of APIs in each matrix, the specific dose of ozone required to achieve reduction by one decade of each investigated API (DDO3) was determined for each effluent by fitting a first order equation to the remaining concentration of API at each applied ozone dose. Ozone dose requirements were found to vary significantly between effluents depending on their matrix characteristics. The specific ozone dose was then normalized to the dissolved organic carbon (DOC) of each effluent. The DDO3/DOC ratios were comparable for each API between the effluents. 15 of the 42 investigated APIs could be classified as easily degradable (DDO3/DOC <= 0.7), while 19 were moderately degradable (0.7 < DDO3/DOC <= 1.4), and 8 were recalcitrant towards O-3-treatment (DDO3/DOC > 1.4). Furthermore, we predict that a reasonable estimate of the ozone dose required to remove any of the investigated APIs may be attained by multiplying the experimental average DDO3/DOC obtained with the actual DOC of any effluent. (C) 2013 Elsevier B.V. All rights reserved.
|
|
| 5. |
- Antoniou, Maria G., et al.
(författare)
-
Variability in required ozone doses for removing pharmaceuticals from wastewater effluents
- 2013
-
Ingår i: Proceedings of the 13th International Conference on Environmental Science and Technology. - : Global Nest, Secretariat. - 9789607475510
-
Konferensbidrag (refereegranskat)abstract
- Aim of study. The aim of the present study was to investigate the ozone dosage required to remove active pharmaceutical ingredients (APIs) from biologically treated wastewater of varying quality originating from different wastewater treatment processes. Methods. Secondary effluents from six Swedish wastewater treatment plants (VWVTP) were spiked with 42 APIs (nominal concentration 1pg/L) and treated with different 03 doses (0.5-12.0 mg/L ozone) in bench-scale experiments (Antoniou et al, 2012). Concentrations of APIs were measured by SPE extraction using OASIS HLB cartridges followed by quantification using LC-MS-MS (Grabic et al, 2012).. Results. For each wastewater effluent a profile of sensitivity of each API to a range of ozone doses were generated as shown in Figure 1.
|
|
| 6. |
- Eriksson, Eva, 1973-, et al.
(författare)
-
Greywater pollution variability and loadings
- 2009
-
Ingår i: Ecological Engineering. - : Elsevier BV. - 0925-8574 .- 1872-6992. ; 35:5, s. 661-669
-
Tidskriftsartikel (refereegranskat)abstract
- Small on-site greywater treatment and reuse plants are susceptible to high short-term variation in flow and pollutant concentrations. As demonstrated in this study of a bathroom greywater plant in Copenhagen, Denmark, the flow ranges from no-flow periods to high-flow periods reaching 34 l min−1. Concentrations of both macro- and micro-pollutants (organic matter and parabens) were found to range by several orders of magnitude in the influent, based on sampling every 20 min. Paraben degradation was proven to occur in the rotating biological contactor (RBC), while the remnant organic matter in the effluent was proved not to be readily degradable. Ammonium content, presumably from urine contamination, was found to undergo nitrification in the RBC. Mass flow (daily loads) for individual substances was calculated for several pollutants. Macropollutants were found to be generated in low numbers of grams per person per day, whereas the paraben loadings were below 1 mg per person per day. These data are highly relevant for comparing decentralised treatment options with existing end-of-pipe treatments, for feeding into risk assessments and for design purposes.
|
|
| 7. |
- Eriksson, Eva, 1973-, et al.
(författare)
-
Substance flow analysis and source mapping of chemical UV-filters
- 2008
-
Ingår i: Water, Air & Soil Pollution: Focus. - : Springer Science and Business Media LLC. - 1567-7230 .- 1573-2940. ; 8:5-6, s. 473-484
-
Tidskriftsartikel (refereegranskat)abstract
- Chemical ultraviolet (UV)-filters are used in sunscreens to protect the skin from harmful UV radiation which may otherwise cause sunburns and skin cancer. Commonly used chemical UV-filters are known to cause endocrine disrupting effects in both aquatic and terrestrial animals as well as in human skin cells. Here, source mapping and substance flow analysis were applied to find the sources of six UV-filters (oxybenzone, avobenzone, 4-methylbenzylidene camphor, octyl methoxycinnamate, octyl dimethyl PABA and homosalate) and to identify the most dominant flows of these substances in Denmark. Urban water, composed of wastewater and surface waters, was found to be the primary recipient of UV-filters, whereby wastewater received an estimated 8.5–65 tonnes and surface waters received 7.1–51 tonnes in 2005. In wastewater treatment plants, their sorption onto sludge is perceived to be an important process and presence in effluents can be expected due to a lack of biodegradability. In addition, the use of UV-filters is expected to continue to increase significantly. Not all filters (e.g., octyl dimethyl PABA and homosalate) are used in Denmark. For example, 4-MBC is mainly associated with self-tanning liquids and private import of sunscreens.
|
|
| 8. |
- Eriksson, Eva, 1973-, et al.
(författare)
-
Substance flow analysis of parabens in Denmark complemented with a survey of presence and frequency in various commodities
- 2008
-
Ingår i: Journal of Hazardous Materials. - : Elsevier BV. - 0304-3894 .- 1873-3336. ; 156:1-3, s. 240-259
-
Tidskriftsartikel (refereegranskat)abstract
- Parabens are commonly used as preservatives due to anti-bactericidal and anti-fungicidal properties and they are ubiquitously present in personal care products, pharmaceuticals, food, industrial and domestic commodities. They are suspected of causing endocrine disrupting effects to aquatic organisms and adverse effects in humans and, thus, it is highly relevant to identify and quantify their sources and transportation pathways in the urban environment. Here a substance flow analysis (SFA) was performed in order to map and comprehend the substances’ flow on a national basis. Many household commodities were found to contain parabens; cleaning detergents, slimy toys, and water-based paint. The presence and concentration of parabens are regulated in cosmetics and food. Use of parabens in pharmaceuticals as excipients is documented in Denmark. The import of parabens is increasing; although the number of industrial parabens containing commodities is decreasing and manufacturer reports phase-out of parabens. The vast majority of the paraben containing commodities has a durability of 18–30 months, thus the average lifetime of the paraben stock is perceived to be limited. The inflow was ca. 154 tonnes via pure chemicals and 7.2–73 tonnes via commodities in 2004. This corresponds to an average wastewater concentration of 640–900 μg/L, when excluding discharge to solid waste, soil, biodegradation and metabolism. This is in the same order of magnitudes as can be found in industrial wastewater but higher than that seen in domestic wastewater. The data needed for the SFA is sparse, dispersed, and difficult to access and associated with a great deal of uncertainty.
|
|
| 9. |
- Grut, Viktor, et al.
(författare)
-
Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis
- 2024
-
Ingår i: Brain. - : Oxford University Press. - 0006-8950 .- 1460-2156. ; 147:1, s. 177-185
-
Tidskriftsartikel (refereegranskat)abstract
- Recent research indicates that multiple sclerosis is preceded by a prodromal phase with elevated levels of serum neurofilament light chain (sNfL), a marker of axonal injury. The effect of environmental risk factors on the extent of axonal injury during this prodrome is unknown. Human herpesvirus 6A (HHV-6A) is associated with an increased risk of developing multiple sclerosis. The objective of this study was to determine if HHV-6A serostatus is associated with the level of sNfL in the multiple sclerosis prodrome, which would support a causative role of HHV-6A.A nested case-control study was performed by crosslinking multiple sclerosis registries with Swedish biobanks. Individuals with biobank samples collected before the clinical onset of multiple sclerosis were included as cases. Controls without multiple sclerosis were randomly selected, matched for biobank, sex, sampling date and age. Serostatus of HHV-6A and Epstein-Barr virus was analysed with a bead-based multiplex assay. The concentration of sNfL was analysed with single molecule array technology. The association between HHV-6A serology and sNfL was assessed by stratified t-tests and linear regressions, adjusted for Epstein-Barr virus serostatus and sampling age. Within-pair ratios of HHV-6A seroreactivity and sNfL were calculated for each case and its matched control. To assess the temporal relationship between HHV-6A antibodies and sNfL, these ratios were plotted against the time to the clinical onset of multiple sclerosis and compared using locally estimated scatterplot smoothing regressions with 95% confidence intervals (CI).Samples from 519 matched case-control pairs were included. In cases, seropositivity of HHV-6A was significantly associated with the level of sNfL (+11%, 95% CI 0.2-24%, P = 0.045) and most pronounced in the younger half of the cases (+24%, 95% CI 6-45%, P = 0.007). No such associations were observed among the controls. Increasing seroreactivity against HHV-6A was detectable before the rise of sNfL (significant within-pair ratios from 13.6 years versus 6.6 years before the clinical onset of multiple sclerosis).In this study, we describe the association between HHV-6A antibodies and the degree of axonal injury in the multiple sclerosis prodrome. The findings indicate that elevated HHV-6A antibodies both precede and are associated with a higher degree of axonal injury, supporting the hypothesis that HHV-6A infection may contribute to multiple sclerosis development in a proportion of cases.
|
|
| 10. |
- Hansen, Aleksander L., et al.
(författare)
-
Birthweight is associated with clinical characteristics in people with recently diagnosed type 2 diabetes
- 2023
-
Ingår i: Diabetologia. - 0012-186X. ; 66:9, s. 1680-1692
-
Tidskriftsartikel (refereegranskat)abstract
- Aims/hypothesis: Low birthweight is a risk factor for type 2 diabetes but it is unknown whether low birthweight is associated with distinct clinical characteristics at disease onset. We examined whether a lower or higher birthweight in type 2 diabetes is associated with clinically relevant characteristics at disease onset. Methods: Midwife records were traced for 6866 individuals with type 2 diabetes in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort. Using a cross-sectional design, we assessed age at diagnosis, anthropomorphic measures, comorbidities, medications, metabolic variables and family history of type 2 diabetes in individuals with the lowest 25% of birthweight (<3000 g) and highest 25% of birthweight (>3700 g), compared with a birthweight of 3000–3700 g as reference, using log-binomial and Poisson regression. Continuous relationships across the entire birthweight spectrum were assessed with linear and restricted cubic spline regression. Weighted polygenic scores (PS) for type 2 diabetes and birthweight were calculated to assess the impact of genetic predispositions. Results: Each 1000 g decrease in birthweight was associated with a 3.3 year (95% CI 2.9, 3.8) younger age of diabetes onset, 1.5 kg/m2 (95% CI 1.2, 1.7) lower BMI and 3.9 cm (95% CI 3.3, 4.5) smaller waist circumference. Compared with the reference birthweight, a birthweight of <3000 g was associated with more overall comorbidity (prevalence ratio [PR] for Charlson Comorbidity Index Score ≥3 was 1.36 [95% CI 1.07, 1.73]), having a systolic BP ≥155 mmHg (PR 1.26 [95% CI 0.99, 1.59]), lower prevalence of diabetes-associated neurological disease, less likelihood of family history of type 2 diabetes, use of three or more glucose-lowering drugs (PR 1.33 [95% CI 1.06, 1.65]) and use of three or more antihypertensive drugs (PR 1.09 [95% CI 0.99, 1.20]). Clinically defined low birthweight (<2500 g) yielded stronger associations. Most associations between birthweight and clinical characteristics appeared linear, and a higher birthweight was associated with characteristics mirroring lower birthweight in opposite directions. Results were robust to adjustments for PS representing weighted genetic predisposition for type 2 diabetes and birthweight. Conclusion/interpretation: Despite younger age at diagnosis, and fewer individuals with obesity and family history of type 2 diabetes, a birthweight <3000 g was associated with more comorbidities, including a higher systolic BP, as well as with greater use of glucose-lowering and antihypertensive medications, in individuals with recently diagnosed type 2 diabetes.
|
|
